Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma

Authors: Feng Yao, Tiejun Zhao, Chenxi Zhong, Ji Zhu, Heng Zhao

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common lethal tumors in the world, and the development of new therapeutic targets is needed. Recent studies have shown that aerobic glycolysis, also known as the Warburg effect, mediated the anti-apoptotic effects in cancer cells. Lactate dehydrogenase A (LDHA) which executed the final step of aerobic lactate production has been reported to be involved in the tumor progression. However, the function of LDHA in ESCC has not been investigated. In this study, it was found that LDHA was up-regulated in ESCC clinical samples. Knockdown of the expression of LDHA inhibited cell growth and cell migration in vitro as well as tumorigenesis in vivo. With regard to the molecular mechanism, silencing the expression of LDHA was related to decreased AKT activation and cyclin D1 expression and increased cleavage of PARP and caspase 8. Taken together, our findings suggest that LDHA plays an important role in the progression of ESCC by modulating cell growth, and LDHA might be a potential therapeutic target in ESCC.
Literature
1.
Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem. 2007;282(50):36571–81.PubMedCrossRef
2.
Zhou ZQ, Cao WH, Xie JJ, et al. Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer. 2009;9:291.PubMedCrossRef
3.
4.
Lewis BC, Shim H, Li Q, et al. Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol. 1997;17:967–78.
5.
Shim H, Dolde C, Lewis BC, et al. C-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94:6658–63.PubMedCrossRef
6.
Cai Z, Zhao JS, Li JJ, et al. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics. 2010;9(12):2617–28.PubMedCrossRef
7.
Huang L, Zheng M, Zhou QM, et al. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011;117(15):3363–73.PubMedCrossRef
8.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.PubMedCrossRef
9.
Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24S–42.PubMedCrossRef
10.
Martínez-Zaguilán R, Seftor EA, Seftor RE, et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis. 1996;14:176–86.PubMedCrossRef
11.
Schlappack OK, Zimmermann A, Hill PR. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer. 1991;64:663–70.PubMedCrossRef
12.
Firth J, Ebert B, Pugh C, et al. Oxygen-regulated control elements in the phosphoglycerate kinase I and lactate dehydrogenase A genes: similarities with the erythropoietin 3′enhancer. Proc Natl Acad Sci USA. 1994;91:6496–500.PubMedCrossRef
13.
Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;6:425–34.CrossRef
14.
15.
Maher JC, Krishan A, Lampidis T. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic condition. Cancer Chemother Pharmacol. 2004;53:116–22.PubMedCrossRef
16.
Maschek G, Savaraj N, Priebe W, et al. 2-Deoxy-d-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and nonsmall cell lung cancers in vivo. Cancer Res. 2004;64:31–4.PubMedCrossRef
Metadata
Title
LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma
Authors
Feng Yao
Tiejun Zhao
Chenxi Zhong
Ji Zhu
Heng Zhao
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0506-0

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue

Research Article

Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism

Research Article

Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines

Research Article

Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway

Research Article

A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population

Research Article

Apoptin selectively induces the apoptosis of tumor cells by suppressing the transcription of HSP70

Research Article

Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits